US biotech PureTech Health (LSE: PRTC) has named Atul Pande as its chief medical officer.
Dr Pande has more than two decades of experience in drug development including as head of neuroscience and senior advisor in pharmaceutical research and development (R&D) for UK pharma major GlaxoSmithKline (LSE: GSK).
He has also been involved in the development of multiple investigational and now marketed drugs while in senior roles with Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze